BOLD PREDICTION
2009 was the last year that ARIA will operate in the RED.
Beginning with 2010, ARIA will report profitable results for many years into the future, and here is why.
1- Based upon the financial results reported today, ARIA has a lock on ending 2010 in the BLACK.
2- Based upon their statement today that they will be reporting milestone payments as current income (and not amortized)
Aria, even if they do not have any Rida drug sales in 2011, will most likely be profitable from the milestone payments alone. If, as I expect, Rida is approved prior 12/31/11, then the sales of Rida in 2011, will only add to the company's profitability. We may also pick up some more EPS if 534 is partnered in 2010 or 2011. ARIA may also get some additional EPS in 2011 from sales of 534 on a compassionate basis, especially with patients who suffer from the T315 mutation.
3- Looking ahead to 2012, sales of Rida and additional milestone payments will again make this a profitable company and we might even see some sales from 534, either as an approved drug or compassionate sales.
4- Looking further ahead, and by 2013, there is no doubt in my mind that with two solid oncology drugs, ARIAD'S EPS will be solid and growing exponentially.
So, Bye, and good riddens , to all the RED INK, and HELLO and WELCOME to PROFITABILITY>
JMHO, Barry
